Effect of fezolinetant on moderate-to-severe vasomotor symptoms in subgroups based on hormone therapy history: pooled data from two randomized phase 3 studies

被引：0

作者：

Santoro, Nanette ^{[1
]}

Neal-Perry, Genevieve ^{[2
]}

Stute, Petra ^{[3
]}

Blogg, Martin ^{[4
]}

Mancuso, Shayna ^{[5
]}

Morga, Antonia ^{[4
]}

Ottery, Faith D. ^{[5
]}

Siddiqui, Emad ^{[4
]}

机构：

[1] Univ Colorado, Sch Med, Aurora, CO USA

[2] UNC Sch Med, Chapel Hill, NC USA

[3] Inselspital Bern, Bern, Switzerland

[4] Astellas Pharma Europe Ltd, Addlestone, Surrey, England

[5] Astellas Pharma Global Dev Inc, Northbrook, IL USA

来源：

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2023年 / 30卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

S-8

引用

页码：1259 / 1259

页数：1

共 50 条

[31] Incidence of cardiovascular events in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab: pooled analysis from a phase 2 and two phase 3 trials [J].

Bissonnette, R. ;

Fernandez-Penas, P. ;

Puig, L. ;

Peserico, A. ;

Fumero, E. ;

Mendelsohn, A. ;

Rozzo, S. ;

Menter, A. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 :46-47

[32] Effect Of Roflumilast On Exacerbations In Patients With Severe COPD And A History Of Hospitalization Receiving Inhaled Combination Therapy: A Pooled Analysis Of Two Randomized Phase 4 Studies [J].

Martinez, F. J. ;

Rabe, K. F. ;

Calverley, P. ;

Fabbri, L. M. ;

Sethi, S. ;

Pizzichini, E. ;

McIvor, A. ;

Anzueto, A. ;

Alagappan, V. ;

Saddiqui, S. ;

Reisner, C. ;

Zetterstrand, S. ;

Roman, J. ;

Bagul, N. ;

Rennard, S. I. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195

[33] Efficacy and safety of oral tofacitinib in North American patients with moderate to severe plaque psoriasis: Pooled analyses of data from randomized phase 3 studies [J].

Korman, Neil J. ;

King, Brett ;

Wolk, Robert ;

Tan, Huaming ;

Kaur, Mandeep ;

Robertson, Debbie ;

Langley, Richard .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) :AB247-AB247

[34] Dupilumab in adolescents with moderate-to-severe atopic dermatitis and a history of allergic rhinitis: Subgroup analysis from a randomized phase 3 trial [J].

Sher, L. ;

Siegfried, E. C. ;

Paller, A. S. ;

Soong, W. ;

Blauvelt, A. ;

Hultsch, T. ;

Mina-Osorio, P. ;

Prescilla, R. ;

Chen, Z. ;

Bansal, A. .

ALLERGY, 2019, 74 :582-582

[35] DUPILUMAB TREATMENT REDUCES HOSPITALIZATIONS IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: A POOLED ANALYSIS OF DATA FROM 7 RANDOMIZED, PLACEBO-CONTROLLED STUDIES [J].

Silverberg, J. ;

Rubini, N. ;

Pires, M. C. ;

Rossi, A. ;

Zhang, A. ;

Chen, Z. ;

Levit, N. A. ;

Thomas, R. ;

Shumel, B. ;

Bego, G. .

VALUE IN HEALTH, 2022, 25 (01) :S20-S20

[36] Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis: a pooled analysis of data from seven randomized, placebo-controlled studies [J].

Rubini, N. P. M. ;

Silverberg, J. I. ;

Pires, M. C. ;

Chen, Z. ;

Chao, J. ;

Bego-Le Bagousse, G. .

BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) :E116-E117

[37] The Effect Of Lebrikizumab Therapy On Key Type 2 Biomarkers In Moderate-To-Severe, Uncontrolled Asthma Patients: A Pooled Analysis From Phase 2 Trials [J].

Hanania, N. A. ;

Korenblat, P. ;

Corren, J. ;

Olsson, J. ;

Kamath, N. ;

Gray, S. ;

Martin, N. ;

Holweg, C. T. J. ;

Matthews, J. G. ;

Scheerens, H. ;

Limb, S. L. ;

Korom, S. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193

[38] Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials [J].

Strober, Bruce ;

Warren, Richard B. ;

Foley, Peter ;

Gooderham, Melinda ;

Thaci, Diamant ;

Cullen, Eva ;

Cioffi, Christopher ;

Peterson, Luke ;

Madden, Cynthia ;

Armstrong, April .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) :AB76-AB76

[39] Long-term safety of tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis through 148 weeks from two phase 3 trials [J].

Reich, K. ;

Thaci, D. ;

Pau-Charles, I. ;

Igarashi, A. ;

Ohtsuki, M. ;

Lebwohl, M. ;

Cantrell, W. ;

Rozzo, S. ;

Blauvelt, A. ;

Iversen, L. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 :47-48

[40] Secukinumab shows efficacy regardless of baseline disease severity in subjects with moderate-to-severe plaque psoriasis: a pooled analysis from four phase 3 studies [J].

Spelman, L. J. ;

Blauvelt, A. ;

Loffler, J. ;

Fox, T. ;

Papavassilis, C. .

AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 :73-73

← 1 2 3 4 5 →